Crimean Congo Haemorrhagic Fever 
Vaccine & Immunotherapy


Numbers

News

  • Project milestones & first achievements

    CCHFVACIM reaches key milestones in its first reporting period. The CCHFVACIM project has made significant progress during its first reporting period (January 2024 – June 2025), laying strong foundations for the development of innovative vaccines and immunotherapies against Crimean-Congo Haemorrhagic Fever (CCHF). Among the key achievements, the consortium successfully designed and evaluated multiple mRNA-based vaccine…

  • New Publication!

    Our team developed a rapid, versatile “plug-and-play” pseudotyped virus neutralisation assay that allows scientists to measure immune responses to several dangerous bunyaviruses without needing high-containment (BSL-3/4) facilities.This is a major step forward because: 🔍 Why it matters for CCHFVACIMThe CCHFVACIM project aims to advance vaccines and medical countermeasures against CCHFV. One of our biggest bottlenecks…

  • 🦠 Crimean-Congo Hemorrhagic Fever in Greece: A Rare but Serious Case

    Greek health authorities have reported a confirmed case of Crimean-Congo hemorrhagic fever (CCHF) in a 71-year-old man. Initially presenting with fever, myalgia, and gastrointestinal symptoms, his condition evolved rapidly to include neurological signs and hemorrhages, leading to his death shortly after diagnosis. 🇬🇷 This is Greece’s first CCHF case in 2025 and only the second…